Cell therapy at the point of care: insights from leading experts

Logo

Cell therapy at the point of care: insights from leading experts

Point-of-care manufacturing is transforming how cell therapies are delivered, enabling faster, localized treatment options for patients. In this series of expert talks, leaders in the field discuss recent clinical data, examine innovations driving this shift in approach, and share best practices for success.

Academic POC CAR-T in Canada: Opportunities and Challenges Getting to Market

Dr. Kekre will delve into the many unique challenges faced in the journey to offer CAR T cell therapy to patients across Canada, particularly those who may have otherwise run out of treatment options. Since its inception in 2016, the Canadian Led Immunotherapies Collaborative (CLIC) program has been at the forefront of this innovative treatment approach. By bringing together researchers, clinicians, and patients from across Canada, CLIC has focused on building expertise and expanding capacity for innovation in the rapidly evolving field of cellular immunotherapy.

The program's first clinical trial was launched in 2019, starting with two sites in Canada, but has since grown into a robust network encompassing multiple clinical and manufacturing sites across the country. In this presentation, Dr. Kekre will highlight the story behind the building of research capacity within CLIC, shedding light on the numerous trials and tribulations faced during the process of bringing a cell therapy product, manufactured on the CliniMACS Prodigy® Platform, to market authorization and standard of care in Canada.

Natasha Kekre, MD @ MACS Cell and Gene Therapy Days 2025

Natasha Kekre, MD, Ottawa Hospital Research Institute, Canada

Dr. Natasha Kekre, BSc, MD, MPH, FRCPC

Division of Hematology and the Transplant and Cellular Therapy Program at The Ottawa Hospital, Canada

Dr. Natasha Kekre has been a member of the Department of Medicine, Division of Hematology, and the Transplant and Cellular Therapy Program at The Ottawa Hospital since October 2015. She is also a scientist at the Ottawa Hospital Research Institute and an associate professor of medicine at the University of Ottawa. Dr. Kekre completed her Bachelor’s in Science at the University of Windsor, her medical degree at the University of Ottawa, and trained in Internal Medicine and Hematology there. She pursued a fellowship in stem cell transplantation at the Dana Farber Cancer Institute in Boston, MA, and earned a Master’s degree in Public Health from Harvard University. Her research focuses on early-phase clinical trials and advancing homegrown therapies into clinical practice. Dr. Kekre collaborates with local researchers and national teams to study hematologic malignancies and develop a Canadian CAR T cell platform to bring this promising therapy to Canadian patients.

Latest clinical developments in CAR T cell therapy of autoimmunity

Since the first success of CD19 CAR T cells in treating systemic lupus erythematosus (SLE) more than four years ago, the field of CAR T cells outside of malignant diseases is vibrant. Ever more autoimmune diseases are being treated with CAR T cells, including rheumatologic, but also hematologic, neurologic, dermatologic and also gastroenterological diseases. This presentation will summarize novel developments including toxicities and toxicity management, expand on indications, discuss possible causes of shorter CAR T cell persistence, question immune reconstitution and functional consequences following CAR T, and will touch on mechanistic insights on how CAR T cells achieve responses, what happens in relapse, and if there are biomarkers that predict failure.

Prof. Fabian Müller, MD @ MACS Cell and Gene Therapy Days 2025

Fabian Müller, MD, Uniklinikum Erlangen, Erlangen, Germany

Prof. Fabian Müller, MD

Principal Investigator and Attending Physician in Hematology and Oncology, University Clinic Erlangen, Germany

Prof. Müller obtained his MD in Freiburg, Germany and started his clinical education in Hamburg. With a focus on targeting malignant B cells in his early research career, he did a postdoctoral fellowship with Dr. Ira Pastan, at the NCI on resistance to CD22-targeted therapy in ALL and aggressive lymphoma. After his post-doc he continued the work on B cell targeting in Erlangen, Germany, using first antibody-directed therapies and then CAR T cells with a focus on translational concepts including tumor microenvironment and functional aspects of a patient’s immune system. As head of the CAR T cell unit, he pioneers CAR T cell therapies in novel indications including solid tumors and autoimmune diseases.

Rapid succession of graft engineering and CAR T therapies facilitated by PoC manufacturing

Allogeneic hematopoietic cell transplantations and CAR T cells are being increasingly used for the treatment of neoplastic and immune disorders. Despite remarkable progress, substantial unmet medical needs remain, including accessibility, adverse events, cost, and disease recurrence. In this lecture, Prof Leung will discuss his experience in solving these problems in the USA and in Asia by rapid successions of graft engineering and CAR T therapies facilitated by point-of-care manufacturing.

Prof. Wing Leung @ MACS Cell and Gene Therapy Days 2025

Prof. Wing Leung, Director of the Children's Blood and Cancer Centre, KK Women's and Children's Hospital, Singapore and Prof. at Duke-NUS Medical School, Singapore

Prof. Wing Leung

Director of the Children's Blood and Cancer Centre, KK Women's and Children's Hospital, Singapore and Professor at Duke-NUS Medical School, Singapore

Professor Wing Leung is the Director of the Children's Blood and Cancer Centre at KK Women's and Children's Hospital, Singapore. He is a Professor at Duke-NUS Medical School. Previously, Professor Leung was a faculty member at Johns Hopkins University, and he held the position of Chair of Bone Marrow Transplantation and Cellular Therapy at St. Jude Children's Research Hospital. He also served as the Chair of the Department of Paediatrics at the University of Hong Kong.

Outcomes of low-cost, point-of-care manufactured CAR T cell therapy for B cell acute leukemia and non-hogkin lymphoblastic lymphoma in Vietnam

Purpose: This study aims to analyze the safety and primary efficacy of point-of-care CD19 CAR T cell therapy produced locally at low cost for the treatment of CD19+ B cell acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) in Vietnam.

Methods: A phase 1 clinical trial was conducted from August 2023 to March 2025. CD19 CAR T cells for 8 ALL patients and 8 NHL patients were manufactured using the automated CliniMACS Prodigy® System. CAR T cells were infused with doses ranging from 0.54 to 2.17×106 cells/kg.

Results: The number and percentage of CAR T cells at harvest were comparable between the 12-day and 8-day culture groups; however, viability was significantly better in the latter group (p=0.01). Upon treatment, the most common side effects included cytokine release syndrome (13 patients) and neurological toxicity (2 patients). No mortality related to CAR T therapy was observed. All ALL patients achieved complete remission after CAR T cell infusion on day 30. At 6 months, 5 patients (62.5%) remained in complete remission. 7 out of 8 NHL patients achieved complete remission on day 90, and 6 remained in complete remission at 6 months. One patient is awaiting assessment.

The total cost of CAR T cell therapy was approximately $140,000 per patient, with around $80,000 allocated to the CAR T product and $60,000 for treatment costs.

Conclusion: CD19 CAR T products can be produced at low cost. CAR T treatment is relatively safe and offers a promising therapeutic option for refractory/relapsed CD19+ NHL and ALL in a developing country like Vietnam.

Low-cost CD19 CAR T can be produced for refractory/relapsed CD19+ NHL and ALL.

Nguyen Thanh Liem, MD @ MACS Cell and Gene Therapy Days 2025

Nguyen Thanh Liem, MD, Vinmec Research Institute of Stem cell and Gene Technology, Hanoi, Vietnam

Prof. Nguyen Thanh Liem, MD

Director of the Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi, Vietnam

Prof. Nguyen Thanh Liem is a pioneer and innovator in pediatric endoscopic surgery and stem cell transplantation. He graduated from Hanoi Medical University in 1976 and completed medical residency program in Surgery at Viet Duc Hospital in 1979. He defended his PhD thesis in 1991 and was appointed as a Medical Professor in Surgery in 2009.

He is an internationally recognized inventor for his seven advanced operative techniques in pediatric surgery. Regarding stem cell studies, Prof. Liem is a pioneer of using stem cell therapy for unmet diseases in children such as cerebral palsy due to oxygen deprivation, due to neonatal icterus, due to intracranial hemorrhage, neurological sequelae after near death drowning, autism, bronchopulmonary dysplasia, and liver cirrhosis due to biliary atresia. Throughout his career, he has been in charge of a number of important positions such as Director of Vietnam National Children Hospital from 2002 to 2012; Director of Vinmec International Hospital from 2013-2016; Vice President of Asian Association of Pediatric Surgery; President of Vietnam Association of Pediatric Surgery. Currently, Prof. Liem is the director of Vinmec Research Institute of Stem Cell and Gene Technology.

He has published 135 studies on the international journals and over 200 papers on domestic journals. He is the editor and author of six chapters of the book titled, “Cell Therapy: Stem Cells and Regenerative Medicine”, which is shortly published by Springer Nature in 2025. He is also the co-author of surgery pediatrics textbooks published in the UK and the US, such as Operative Pediatric Surgery, Ashcraft’s Pediatric Surgery, and Pediatric Laparoscopic and Thoracoscopic Surgery.

Prof. Nguyen Thanh Liem has been invited to give lectures and performed demonstrative surgeries in many countries including the US, France, Netherlands, Italia, Australia, Japan, India, South Korea, and more.

By his dedicated and delightful contributions to the medical practices and research, he has been honored many prestige awards conferred by the Vietnam government like the Ho Chi Minh Award, National Labor Hero Medal and Award of Vietnam Talent.

In 2018, he has been awarded the 2018 Nikkei Asia Prize in the Science and Technology category thanks to his contribution to develop and popularize pediatric endoscopic surgery in Asia and the world. He is categorized in the top 100 scientists in Asia by the Singapore Journal in 2019.

PoC manufacturing of CAR T therapy in Slovenia

Chimeric antigen receptor (CAR) T cell therapy transformed hematologic cancer treatment, however, it faces barriers due to centralized, expensive manufacturing. Academic, point-of-care (PoC), and distributed models are faster and more affordable alternatives. PoC production near hospitals improves turnaround and cell quality, with platforms like the CliniMACS Prodigy® Platform achieving >85% success in 7–14 days. However, infrastructure, staffing, and regulatory problems persist. Distributed manufacturing scales PoC benefits across networks, requiring harmonized protocols and centralized vector sourcing.

Academic and PoC models show comparable safety and efficacy to commercial products, with costs as low as $35,000–$90,000 versus the range of $400,000 for commercial CAR T cell therapy. Accessibility remains uneven, but decentralized approaches may improve equity. Success depends on regulatory support, investment, and collaboration. Approach to PoC, academic CAR T cell program at UMC Ljubljana, Slovenia, will be presented in more detail.

Matjaz Sever, MD @ MACS Cell and Gene Therapy Days 2025

Matjaz Sever, MD, University Clinical Center Ljubljana, Ljubljana, Slovenia

Prof. Matjaz Sever, MD

Professor of Hematology, University Medical Center Ljubljana, Slovenia

Matjaz Sever is Professor of Hematology at the University Medical Center Ljubljana, Slovenia. He graduated in Hematology in 2009 and then undertook training in hematology and stem cell transplant at the Hammersmith Hospital, Imperial College London, London, UK, before taking up his current position as Head of the stem cell transplant program.

Prof. Sever has extensive research experience, having worked as a postdoctoral fellow (Leukemia department, MD Anderson Cancer Center, Houston, Texas, USA) and PhD student (Medical faculty, University of Ljubljana, Slovenia) before graduating with a PhD in 2013. He is conducting several clinical and preclinical studies in diagnostics of myeloproliferative neoplasms and stem cell therapies for various medical conditions. His research has been published in numerous, peer-reviewed journals. In addition, Matjaz Sever is a member of the European Bone Marrow Transplant Group, American Society of Hematology and Slovenian Society of Hematology.

Academic model for CAR T development in multiple myeloma: clinical results with ARI0002h and future plans

The introduction of B cell maturation antigen (BCMA) directed chimeric antigen receptor T cell (CAR T) therapy to the treatment of relapsed/refractory (R/R) multiple myeloma (MM) is undoubtedly revolutionary. Consequently, the demand for this therapy overcomes availability, and in some countries and health systems, the costs of this therapy are unaffordable. These unmet needs may be improved by academic CAR Ts.

Our institution developed ARI0002h, a second-generation 4-1BB-based CAR, with a humanized scFv directed against BCMA. A pivotal, single-arm, open-label clinical trial (CARTBCMA-HCB-01) for the treatment of R/R MM patients was performed in 7 Spanish centers across the country with two CAR T cell production centers.

A booster dose of up to 3x106 CAR+cells/kg was planned at least 3 months after the first dose. Results of the first cohort of 30 patients showed an overall response rate (ORR) of 100% with 67% achieving complete responses (CR). In a more recent update, with 60 patients treated, the overall response rate in the first 3 months was 95%. ARI0002h administered in a fractioned manner with a booster dose can provide deep and sustained responses in patients with R/R MM, with relatively low-grade toxicity, especially neurologic events, and the possibility of a point-of-care approach.

Prof. Carlos Fernández de Larrea, MD @ EBMT 2025

Carlos Fernández de Larrea, MD, Hematologist and Principal Investigator, Hospital Clínic Barcelona, Spain

Prof. Carlos Fernández De Larrea, MD

Hematologist and Principal Investigator, Hospital Clinic Barcelona, Spain

Carlos Fernández de Larrea completed his training in hematology at Hospital Clínic in Barcelona. His doctoral thesis was awarded with the Extraordinary Award of the University of Barcelona (2012). He has been a visiting investigator at the Centre for Amyloidosis of Pavia, the National Cancer Institute in Bethesda, as well as at Memorial Sloan Kettering Cancer Center in New York for 18 months, working in CAR T cells for myeloma.

He is currently a consultant of the Department of Hematology at Hospital Clínic de Barcelona, research group leader at IDIBAPS, and Associate Professor at the University of Barcelona. He participates actively in clinical trials for multiple myeloma and macroglobulinemia, particularly with the development of academic CAR T cells for monoclonal gammopathies, either from the pre-clinical perspective or multicenter clinical trials.

Point of care manufacturing models: GMP aspects and regulatory pathways

This webinar provides an overview of different approaches in point-of-care (PoC) manufacturing of cell and gene therapies. The presenters discuss the tools currently available, the main regulatory frameworks for establishing them, and their possible future development.

Moderator: Georgia Fodelinaki, PhD (Global Product Manager Immunotherapy, Miltenyi Biotec)

Cristina Conforti Andreoni, PhD

Portfolio Strategy Manager - Immunotherapy, Miltenyi Biotec, Germany

Cristina Conforti Andreoni, PhD, obtained her PhD in Translational Medicine at the University of Milan-Bicocca, Italy, in collaboration with SIgN, A-STAR Singapore, researching the dendritic cell response to danger signals.

After a post-doctoral fellowship on the same project and her role as a scientific officer at the biotech startup Ayoxxa at National University of Singapore, she joined Miltenyi Biotec in Bergisch Gladbach, Germany as Global Product Manager for the cell culture portfolio. In 2018, she took over as Group Leader for Translational Immunology with focus on myeloid cells, B cells, and NK cells. Since 2022, she is Portfolio Strategy Manager for Immunotherapy.

Bernd Schröder

Global Head of Regulatory Affairs, Miltenyi Biotec

Bernd Schröder is the Global Head of Regulatory Affairs at Miltenyi Biotec. After 6 years experience in cell and gene therapy at MainGen, he joined Miltenyi Biotec as Head of Fermentation to build up the manufacturing of antibodies and cytokines.

Since 2014, he is responsible as Global Head of Regulatory Affairs, e.g. for medical devices, raw and starting material for cell and gene therapy, viral vectors, and instruments. Since 2009, Bernd Schröder is Qualified Person according to §14 German Drug Law for procurement and marketing of tissue products as well as for biopharmaceutical products since 2011.

Erwan Gicquel, PharmD, Government Affairs Lead, Europe, Miltenyi Biomedicine

Erwan Gicquel, PhD

Government Affairs Lead, Europe, Miltenyi Biomedicine

Located in Brussels, Erwan coordinates Miltenyi Biomedicine’s public policy and government affairs activities in Europe, in partnership with Miltenyi Biotec. His primary responsibilities consist of monitoring public health, research and market access policies, e.g. in relation to cell and gene therapies, rare diseases, and cancer.

Erwan serves as the primary liaison between the company, the institutions of the European Union, and our European trade associations. Erwan has worked in public policy and government affairs in Europe since 2002, having served in similar roles at Celgene, Biogen, Novo Nordisk, Pfizer, and EuropaBio. Erwan previously worked as a research scientist at UCB Pharmaceuticals before beginning his career in public policy. He has a Bachelor degree in Microbiology and Toxicology, a Master Degree in Toxicology, and Doctorate in Pharmacy.

Enabling effective simultaneous immunosuppression and support of immune regulation by CRISPR/Cas9 edited tacrolimus-resistant Tregs

Regulatory T cells (Tregs) restore immune balance (e.g., after transplantation), however, immunosuppression required to suppress alloreactive effector-T cells compromises their function. Based on our expertise with regulatory T cell therapy, we developed and characterized a CRISPR/Cas9-ribonucleoprotein-based tacrolimus-resistant Treg product in depth.

Subsequently, we successfully performed technology transfer to our in-house GMP facility and finally obtained manufacturing authorization to produce this product for clinical trials. A phase I/IIa study in living donor kidney transplant recipients has been applied for and a basket trial involving SOT recipients of different organs is in preparation with support from the ATMP pilot program at the EMA. The application of this product could benefit a wide range of immunological conditions treated with tacrolimus and many learnings have been made on the road to the translation of this unique Treg product.

Leila Amini @ Miltenyi Cell and Gene Therapy Summit 2024

Leila Amini, PhD, Head of Regulatory Affairs BeCAT, Charité, Germany

Leila Amini, PhD

Head of Regulatory Affairs BeCAT, Charité, Germany

Dr. Leila Amini studied Molecular Biomedicine at the University of Bonn and Molecular Medicine at the Charité-Universitätsmedizin Berlin before graduating with a PhD from the Berlin-Brandenburg School for Regenerative Therapies at Charité-Universitätsmedizin Berlin.

As she was always aiming to contribute to the clinical translation of advanced therapies, she specialized in regulatory affairs for ATMPs, and dedicated her research to process development for ATMPs leading a junior group at the BIH-Center for Regenerative Therapies. She additionally leads the Regulatory Affairs Unit at the Berlin Center for Advanced Therapies (BeCAT) and assumes responsibilities at the GMP facility of BeCAT.

Development of CD19 CAR-T IIT in Korea

The cure rate of acute lymphoblastic leukemia (ALL) has improved over the past five decades. The main cause of improvement is owed to the development of chemotherapy, new antibodies, targeted agents, detection of MRD, and the understanding of leukemia biology. Despite the improvement of outcomes in ALL, there are some remaining problems, and the outcome of relapsed/refractory (R/R) patients remains very poor.

To overcome this problem, anti-CD19 chimeric antigen receptor T cells (CAR T) have been developed and approved by the US FDA as a breakthrough therapy for relapsed/refractory ALL with promising results. Unfortunately, Tisa-cel was not introduced to Korea at that time. To treat R/R ALL patients and to make an IIT development system, ‘Clinical study of hospital-manufactured CD19 CAR T in children and adolescents with acute lymphoblastic leukemia (NCT05210907)’ was prepared and started as a first investigator-initiated CAR T trial in Korea at Seoul National University.

Hyoung Jin Kang @ Miltenyi Cell and Gene Therapy Summit 2024

Hyoung Jin Kang, MD, Professor and specialist of Pediatric Hematology and Oncology, Seoul National University Hospital, South Korea

Prof. Hyoung Jin Kang, MD, PhD

Pediatric hematology/oncology, Seoul National University Hospital, South Korea

Developing an academic point of care CAR T network in Canada: the CLIC experience

Access to commercial CAR T cells remains limited,even in countries like Canada, due to clinical, logistical,and financial barriers. As such, we brought together clinicians, researchers, and patients from across Canada to form the Canadian-Led Immunotherapies for Cancer (CLIC) network, and established a non-commercial academic platform for end-to-end manufacturing of CAR T cells that is point-of-care compatible using Miltenyi Biotec’s CliniMACS Prodigy System. In our first trial, CLIC-01, we have treated >75 patients with CD19 CAR T cells with an excellent manufacturing success rate and a median vein-to-vein time of only 2 weeks. We are currently transferring our knowledge to other centers in Canada, enabling the establishment of a larger network of manufacturing sites with similar processes and procedures. During this session, we will discuss the particular challenges and opportunities with developing a point-of-care network across a large geography, and how such initiatives can help improve access for patients and to innovative therapies in a publicly funded healthcare system.

Kevin Hey @ 50th Annual Meeting of EBMT 2024

Prof. Kevin Hay, MD

Clinical hematologist at the Tom Baker Cancer Centre and Associate Professor in Medicine at the University of Calgary

Prof. Kevin Hay is a clinical hematologist at the Tom Baker Cancer Centre (Calgary,
Canada) and Associate Professor in Medicine at the University of Calgary with a focus on
the pre-clinical development and translation of adoptive cell therapies.

He completed a postdoctoral fellowship with Cameron Turtle at Fred Hutchinson Cancer Research Centre (Seattle, USA), and then took a position with BC Cancer (Vancouver, Canada) to help develop a research CAR T cell program before moving to Calgary in 2023.

He continues to serve as Medical Director of the BC Cancer Conconi Family Immunotherapy Laboratory (Victoria, Canada) which is dedicated to the manufacturing of cellular immunotherapies, and maintains a research laboratory both at the BC Cancer Research Institute (Vancouver, Canada) and the Charbonneau Cancer Institute (Calgary, Canada).

Empowering patient care: IPC/QC solutions for cellular therapies

Standardized in-process and quality controls (IPC/QC) that enable compliance with regulatory guidelines are critical for reliable assessment of the safety and efficacy of cellular therapies throughout cell manufacturing workflows. In this informative session we dive into the strategies to optimize point-of-care practices, focusing on analytical development and release testing.

Webinar given by Christin Tischner, PhD and Simon Lennartz, MSc

Simon Lennartz

Simon Lennartz, MSc

Doctoral Candidate at Universitätsklinikum Köln

Simon Lennartz is currently working on his PhD thesis at the Uniklinik Köln, where he oversees the development of new CAR and TCR strategies to improve adoptive T cell therapy.

Point-of-care CAR T cell manufacturing in Canada: CLIC-01 CD19 clinical trial

Developing a country-wide program to make lifesaving CAR T cell therapy accessible to patients is no small feat. In Canada, Dr. Natasha Kekre has been instrumental in driving the Canadian-Led Immunotherapies in Cancer (CLIC) research program to make this a reality. In this webinar, Dr. Kekre of The Ottawa Hospital will present the multitude of unique challenges involved and how the program overcame them to offer CAR T cell therapy to patients across Canada who may otherwise be out of options.

Webinar given by Dr. Natasha Kekre, BSc, MD, MPH, FRCPC

Natasha Kekre, MD, Ottawa Hospital Research Institute, Canada

Dr. Natasha Kekre, BSc, MD, MPH, FRCPC

Transplant and Cellular Therapy Program, The Ottawa Hospital, Canada

Natasha Kekre, BSc, MD, MPH, FRCPC, is a hematologist in the Transplant and Cellular Therapy Program at The Ottawa Hospital. She is also an associate scientist at the Ottawa Hospital Research Institute and Associate Professor of Medicine at the University of Ottawa.

She completed her Bachelor of Science at the University of Windsor and then obtained her medical degree from the University of Ottawa. She then trained at the University of Ottawa in internal medicine and hematology. She went on to do a fellowship in stem cell transplantation at Dana Farber Cancer Institute in Boston, MA with a Master’s in Public Health from Harvard University. Her research is focused on developing early-phase clinical trials and moving homegrown therapeutic strategies to patients to treat hematologic malignancies.

Current status and challenges of cell and gene therapies in India​

The Department of Hematology at Christian Medical College, Vellore, India, has had an active hematopoietic cell transplant (HCT) program since 1986, performing 300+ HCT a year, of which around 250 allogeneic HCT, including haplo-identical HCT with graft manipulation in the pre- and post-PTCy era, and with CD34 selection transplants in the earlier era. There is an increased interest in graft manipulation for HCT, as well as using cell therapy alone as an adjunct to HCT to treat or reduce the risk of relapse in hematological malignancies.

An NK cell program with a phase II study in relapsed refractory acute myeloid leukemia (AML) has just been completed. The preliminary data, in addition to establishing safety, provides a signal to suggest efficacy, and we are keen to move this strategy to high-risk first remission AML HCT.

As viral reactivation is a major challenge in our current haplo-identical HCT program, we initiated a study using anti-cytomegalovirus (CMV)–directed CTL therapy or CD45RA+-depleted donor lymphocyte infusion (DLI) post haplo-identical HCT.

We have also made early steps into establishing a CAR T cell program in collaboration with Miltenyi Biotec. We hope to expand this program to other centers in the country with a decentralized manufacturing approach and to move into gene therapy for inherited hematopoietic disorders such as thalassemia major and sickle cell disease. In this presentation, I give an overview of the status and opportunities of cell and gene therapy in India and illustrate the regulatory pathways that we have followed and challenges that we face.

Dr. Vikram Mathews, MBBS, MD, DM @ Miltenyi Biotec’s Cell and Gene Therapy Days 2023

Dr. Vikram Mathews, MBBS, MD, DM

Head of Department of Hematology, Christian Medical College Vellore, India

Having completed his medical school training at Christian Medical College in 1991, Dr. Vikram Mathews, MBBS, MD, DM, spent two years in primary care hospitals, which included a rural hospital where he was one of two physicians. He subsequently completed his post-graduation in general medicine from the same institution where he had done his undergraduate training, followed by a sub-specialty training in clinical hematology, which he completed in 2001.

Dr. Mathews looked for opportunities to develop his basic science research skills further, obtaining a postdoctoral fellowship at the Stem Cell and Leukemia Unit at Washington University, St. Louis, MO, USA. In his third year at Washington University, he did a clinical bone marrow transplant fellowship. Dr. Mathews returned to India in 2004 and rejoined the Department of Hematology at Christian Medical College, where he is currently Professor of Clinical Hematology and director of the institution.

CAR T manufacturing in an academic institution

At the Hospital Clinic of Barcelona, we have developed a second-generation CAR T (with 4-1BB as a co-stimulatory motif) targeting CD19 (ARI0001 or varnimcabtagene autoleucel), which is fully publicly funded and has received authorization for use under the hospital exemption regulation. It is the first academic and European CAR T approved worldwide for acute lymphoblastic leukemia B and is currently undergoing evaluation under the Priority Medicines (PRIME) designation by the European Medicines Agency (EMA), trying to obtain centralized marketing authorization.

Alongside ARI0001, we are also close to obtaining "hospital exemption" for ARI0002h (cesnicabtagene autoleucel), an anti-BCMA CAR T for multiple myeloma. Obviously, all these academic products meet the same quality requirements as commercial products and must also demonstrate effectiveness within the ranges of commercial products in clinical trials for approval.

Possibly, with these Barcelona products, we are paving the way to enable academic production to provide treatment options in cases where pharmaceutical companies are not interested in developing these products (such as rare diseases like pediatric tumors or even autoimmune diseases to low frequent autoantigens). Beyond cancer, other immune-mediated diseases (such as autoimmune disorders and systemic lupus erythematosus) are probably the next challenges for CAR T immunotherapies.

Marta Español Rego, PhD @ Miltenyi Biotec’s Cell and Gene Therapy Days 2023

Marta Español Rego, PhD

Manufacturing and monitoring of CAR T cell therapies, Hospital Clinic Barcelona, Spain

Marta Español Rego, PhD, works in the immunotherapy section of the Hospital Clinic of Barcelona (HCB). She finished her pharmacy residence in Immunology (FIR) in 2018 at HCB and obtained her PhD in 2023 at the University of Barcelona in the field of dendritic cell immunotherapy in colorectal cancer.

She has completed her immunology studies with a research stay at University Hospital La Paz (Madrid) and at the Center for Cancer Immune Therapy (Denmark), focusing in immunodeficiency diagnosis, molecular biology techniques, and adoptive cell therapy with tumor-infiltrating lymphocytes. She started to work as an immunology specialist at HCB in 2018 and also participates as a professor at University of Barcelona in the Master in Translational Medicine and the Master of Biomedicine. During all this time, Marta has gained experience in transplant immunology, clinical immunology, and immunotherapy. She is mainly involved in the development of anti-tumor immunotherapy as the responsible lead in manufacturing and monitoring of CAR T cell therapy. She is also involved in regulatory aspects of the treatments produced in the Advanced Therapies Unit of the HCB.

You have previously chosen International as your location.
What do you want to do?